阿利克仑合成路线图解
被引量：3
Graphical Synthetic Routes of Aliskiren
摘要
阿利克仑（aliskiren，1），化学名为（2S，4S5S，7S）-5-氨基-N-（2-氨基甲酰基-2-甲基丙基）-4-羟基-2-异丙基-7-[4-甲氧基-3-（3-甲氧基丙氧基）苄基]-8-甲基壬酰胺，是瑞士诺华公司研发的抗高血压药，2007年先后在美国和欧盟批准上市。本品是一种口服有效的作用于肾素血管紧张素醛固酮系统（RAS）的非肽类。肾素抑制剂，是高血压治疗领域推出的首个具有新型药理作用机制的药物。
出处
《中国医药工业杂志》
CAS
CSCD
北大核心
2009年第6期468-473,共6页
Chinese Journal of Pharmaceuticals
基金
国家自然科学基金资助项目(20672069)
山东省自然科学基金(Y2007C060)
参考文献28
-
1Siragy HM, Kar S, Kirkpatrick P. Aliskiren [J]. Nat Rev DrugDiscov, 2007, 6(10) : 779-780.
-
2Jensen C, Herold P, Brunner HR. Aliskiren: the first renin inhibitor for clinical treatment ~J~. Nat Rev Drug Discov, 2008, 7(5): 399-410.
-
3Goeschke R, Stutz S, Rasetti V, et al. Novel 2,7-dialkylsubstituted 5 (S) -amino-4 (S) -hydroxy-8-phenyl- octanecarboxamide transition state peptidomimetics are potent and orally active inhibitors of human renin [J]. JMed Chem, 2007, 50(20) : 4818-4831.
-
4董华,张治柳,马汝建,等.高血压蛋白原酶抑制剂阿利克仑的实用性合成方法:中国,101016253[P].2007-08-15.
-
5Dong H, Zhang ZL, Huang JH, et al. Practical synthesis of an orally active renin inhibitor aliskiren [J]. Tetrahedron Lett, 2005, 46 (37) : 6337-6340.
-
6Lindsay KB, Skrydstrup T, Formal total synthesis of the potent renin inhibitor aliskiren: application of a SmI2- promoted acyl-like radical coupling [J]. J Org Chem, 2006, 71 (13) : 4766-4777.
-
7Sandham DA, Taylor RJ, Carey JS, et al. A convergent synthesis of the renin inhibitor CGP60536B[J]. Tetrahedron Lett, 2000, 41 (51) : 10091-10094.
-
8Rueger H, Stutz S, Goeschke R, et al. A convergent synthesis approach towards CGP60536B, a non-peptide orally potent renin inhibitor, via an enantiomerically pure ketolactone intermediate [J]. Tetrahedron Lett, 2000, 41 (51): 10085-10089.
-
9Dondoni A, De Lathauwer G, Perrone D. A convergent synthesis of the renin inhibitor SPP-100 using a nitrone intermediate [J]. Tetrahedron Lett, 2001, 42(29): 4819-4823.
-
10Bellus D, Dondoni A. Process for the preparation of aryloctanoyl amides: EP, 1215201 [P]. 2003-01-29. (CA 2002, 137: 33135)
同被引文献19
-
1尹淑美,阎圣刚,李刚月,蒋山,廖明义,刘炼.5-硝基愈长木酚的合成[J].广东化工,2007,34(7):25-26. 被引量：2
-
2Tsou E L, Chen S Y, Yang M H, et al. Synthesis and biological evaluation of a 2-aryl polyhydroxylated py,Tolidine alkaloid-based library [J]. Bioorg. Med. Chem., 2008, 16(24): 10198-10204.
-
3Alejandro C D. Kumada-cm-riu cross coupliug route to the anti-cancer agent combretastatin A-4 [J]. Synth. Commun., 2008, 38(21): 3823-3833.
-
4Fujikawa N, Ohta T, Yamaguchi T, et al. Total synthesis of lamellarins D, L, and N [J].Tetrahedron, 2006, 62 (4): 594-604.
-
5Nobuhito K, Tomio I, Masao T. Facile preparation of organozinc bromides using electrogenerated highly reactive zinc and its use in cross-coupling reaction [J]. Tetrahedron, 2005, 61(47): 11125-11131.
-
6Quideau S, Fabre I, Deffieux D. First asymmetric synthesis of orthoquinone monoketal enantiomers via anodic oxidation [J]. Org. Lett., 2004, 6(24): 4571-4573.
-
7Vandermey M, Hatzelmann A, Vanklink G P M, et al. Novel selective PDE4 inhibitors. 2. Synthesis and structure- activity relationships of 4-aryl-substiluted cis-tetra- and eishexahydrophthalazinones [J]. J. Med. Chem., 2001, 44 (16): 2523-2535.
-
8David B S, Corey E J. A two-step total synthesis of the natural pentacyele tlichodimerol, a novel inhibitor of TNF-a production [J]. J. Org. Chem., 2004, 69(25): 8731-8738.
-
9Pinney K G, Sriram M. Combretastatin analogs with tubulin binding activity: W0,2006138427[P]. 2006-11-28.
-
10Dong H, Zhang ZL, Huang JH et al., Practical synthesis of an orally active renin inhibitor aliskiren[J].Tetrahedron Letters, 2005, (46) :6337-6340.
-
1姜林海,王在利,王乐飞,张文烨.卡托普利合成路线图解[J].中国医药工业杂志,1993,24(6):274-276. 被引量：2
-
2任进知,杨福秋,时惠麟,李迪元.肾素抑制剂研究-N-(α-羟基-β-羟基烃基)三肽酯的合成[J].中国医药工业杂志,1989,20(12):535-538.
-
3吴桂平,王有名,周正洪.(2S,4E)-5-氯-2-异丙基-4-戊烯酸乙酯的简易合成[J].精细化工中间体,2012,42(4):40-41.
-
4郭双华.阿利克仑中间体的合成及提纯[J].广州化工,2014,42(16):80-82.
-
5吴建平,丁霄霖.大豆降压肽的研制(Ⅱ)——酶E作用条件的优化[J].中国油脂,1998,23(3):6-8. 被引量：33
-
6郭满芳,鲁颖,田晔,綦秋华,李一平.血管紧张素转化酶抑制剂—马来酸依那普利的合成[J].黑龙江医药,1996,9(1):10-12. 被引量：1
-
7李万玉,余瑜,靳红卫.新型血管紧张素转化酶抑制剂Enalapril的合成研究[J].中国药物化学杂志,1995,5(3):218-220. 被引量：1
-
8刘世峰,徐杰诚.新型血管紧张素转化酶抑制剂——氮杂三肽类似物的合成及结构活性关系[J].化学学报,1998,56(7):707-713.
-
9一些值得期望的药品[J].医药化工,2008(5):38-38.
-
10一些值得期望的药品[J].制药原料及中间体,2008(6):29-30.
